← Browse by Condition
Medical Condition

human papilloma virus hpv

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for human papilloma virus hpv sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — human papilloma virus hpv Clinical Trials

How many clinical trials are currently recruiting for human papilloma virus hpv?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for human papilloma virus hpv, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for human papilloma virus hpv?
human papilloma virus hpv research spans Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a human papilloma virus hpv clinical trial?
Eligibility criteria for human papilloma virus hpv trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
2
Top Sponsors
Verrica Pharmaceuticals Inc. 2 trials
Institut Pasteur du Cambodge 1 trial
University of Texas at Austin 1 trial

Recruiting Clinical Trials

NCT07246590 Phase 3
Recruiting
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Enrollment
300 pts
Location
United States
Sponsor
Verrica Pharmaceuticals Inc.
View Trial →
NCT07358910
Recruiting
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Enrollment
10,000 pts
Location
Cambodia
Sponsor
Institut Pasteur du Cambodge
View Trial →
NCT06825689
Recruiting
Unidos Contra el VPH
Enrollment
735 pts
Location
United States
Sponsor
University of Texas at Austin
View Trial →
NCT07457918 Phase 3
Recruiting
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Enrollment
600 pts
Location
United States
Sponsor
Verrica Pharmaceuticals Inc.
View Trial →

Related Conditions

common warts (2) common warts verruca vulgaris (2) warts (2) dengue (1) chikungunya (1) zika virus infection (1) japanese encephalitis (1) west nile virus (1) tick borne encephalitis tbe (1) severe fever with thrombocytopenia syndrome (1) nipah virus infection (1) hantavirus infections (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology